66. IgA nephropathy Clinical trials / Disease details
Clinical trials : 275 / Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-004795-34-ES (EUCTR) | 05/05/2022 | 02/02/2022 | Safety and Efficacy of AT-1501 in Patients with IgAN | A Phase 2a, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of AT-1501 in Patients with IgA Nephropathy - Safety and Efficacy of AT-1501 in Patients with IgAN | IgA Nephropathy MedDRA version: 20.1;Level: PT;Classification code 10029151;Term: Nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: AT-1501 Product Code: AT-1501 INN or Proposed INN: Not yet assigned Other descriptive name: Not yet assigned | Eledon Pharmaceuticals, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 42 | Phase 2 | Philippines;Thailand;Poland;Malaysia;Spain;Croatia;Australia;Sri Lanka;New Zealand;China | ||
| 2 | NCT05125068 (ClinicalTrials.gov) | March 21, 2022 | 8/11/2021 | Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN) | A Phase 2a, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy | IgA Nephropathy;IgAN | Drug: AT-1501 | Eledon Pharmaceuticals | NULL | Recruiting | 18 Years | 99 Years | All | 42 | Phase 2 | Australia;Croatia;Malaysia;New Zealand;Philippines;Poland;Spain;Thailand;United Kingdom |